IL1B and renal cell carcinoma: Studies have shown that treatments such as IL-1β blockade, ICB, or TKIs can reconfigure the myeloid compartment in the TME through T cell-independent mechanisms, enhancing pro-inflammatory M1-like TAMs and suggesting new immunotherapy strategies for RCC.